University of Oklahoma researchers find FGF21 hormone reverses obesity in mice via brain circuit
Updated
Updated · ScienceDaily · Apr 25
University of Oklahoma researchers find FGF21 hormone reverses obesity in mice via brain circuit
8 articles · Updated · ScienceDaily · Apr 25
The study, published in Cell Reports, reveals FGF21 acts through the hindbrain’s NTS and area postrema, increasing metabolic activity rather than suppressing appetite like GLP-1 drugs.
This newly identified brain circuit could enable more targeted obesity and liver disease therapies, potentially avoiding side effects seen with current FGF21 analogues such as gastrointestinal issues and bone loss.
Researchers hope these findings will lead to improved treatments for obesity and MASH, as drugs targeting FGF21 pathways are already in clinical trials for metabolic liver diseases.
Beyond weight loss, could this discovery be the key to reversing fatty liver disease?
This hormone reverses obesity in mice, but will it overcome drug resistance in humans?
A promising obesity treatment may work, but does it come with a hidden risk to bone health?
Could a newly found brain circuit offer a weight-loss solution without Ozempic's side effects?
With new drugs emerging, will the era of appetite-suppressing weight-loss medications soon be over?
FGF21 Brain Circuit Discovery Drives New Metabolic Fat-Burning Obesity Therapies with 5-8% Weight Loss
Overview
Researchers at the University of Oklahoma uncovered how the hormone FGF21 fights obesity by activating a specific brain circuit in the hindbrain, which signals the parabrachial nucleus to boost metabolism and fat burning without suppressing appetite. This unique mechanism leads to moderate weight loss and improved lipid and insulin profiles. In contrast, GLP-1 receptor agonists reduce appetite and promote fat browning, resulting in greater weight loss. Combining these distinct pathways offers promising new therapies, especially for patients who do not respond well to appetite suppressants. However, challenges like FGF21 resistance in obesity and potential bone loss require ongoing research and safer drug designs to fully harness FGF21's benefits.